LON:OXB Oxford Biomedica (OXB) Share Price, News & Analysis GBX 607 -3.00 (-0.49%) As of 12:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Oxford Biomedica Stock (LON:OXB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Oxford Biomedica alerts:Sign Up Key Stats Today's Range 604▼ 63550-Day Range 550▼ 65952-Week Range 305.50▼ 952Volume165,076 shsAverage Volume691,230 shsMarket Capitalization£734.52 millionP/E RatioN/ADividend Yield4.57%Price TargetGBX 604.32Consensus RatingModerate Buy Company Overview Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube. Read More Receive OXB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oxford Biomedica and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OXB Stock News HeadlinesHow Oxford Biomedica (LSE:OXB) Is Reframing Its Long Term Value Story Around £8.43May 22, 2026 | finance.yahoo.comHow I invested my first £1,000 in FTSE shares… and the mistakes I madeApril 25, 2026 | uk.finance.yahoo.comStranded On The Flood Plains of HistoryThe petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar.June 18 at 1:00 AM | Porter & Company (Ad)57% under ‘fair value’ and 74% forecast earnings growth! 1 FTSE high-tech med stock I just can’t pass upApril 20, 2026 | uk.finance.yahoo.comOxford Biomedica unveils fast-track viral vector service to speed gene therapy developmentApril 14, 2026 | theglobeandmail.comOxford Biomedica Confirms Updated Total Voting RightsApril 11, 2026 | theglobeandmail.comOxford BioMedica PLC (LSE:OXB) Q4 2025 Earnings Report Preview: What To ExpectMarch 25, 2026 | finance.yahoo.comAn Intrinsic Calculation For Oxford Biomedica plc (LON:OXB) Suggests It's 47% UndervaluedJanuary 15, 2026 | finance.yahoo.comSee More Headlines OXB Stock Analysis - Frequently Asked Questions How have OXB shares performed this year? Oxford Biomedica's stock was trading at GBX 617 on January 1st, 2026. Since then, OXB stock has decreased by 1.6% and is now trading at GBX 607. How were Oxford Biomedica's earnings last quarter? Oxford Biomedica plc (LON:OXB) issued its earnings results on Thursday, March, 26th. The biopharmaceutical company reported ($26.92) earnings per share (EPS) for the quarter. Oxford Biomedica had a negative trailing twelve-month return on equity of 48.56% and a negative net margin of 17.85%. Read the conference call transcript. How do I buy shares of Oxford Biomedica? Shares of OXB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Oxford Biomedica own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oxford Biomedica investors own include EnQuest (ENQ), Petra Diamonds (PDL), Centamin (CEY), Lloyds Banking Group (LLOY), Oxford BioMedica (OXBDF) and Barclays (BARC). Company Calendar Last Earnings3/26/2026Today6/18/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:OXB CIKN/A Webwww.oxfordbiomedica.co.uk Phone+44-1865-783000FaxN/AEmployees891Year FoundedN/APrice Target and Rating Average Price Target for Oxford BiomedicaGBX 604.32 High Price TargetGBX 1,170 Low Price TargetGBX 8.27 Potential Upside/Downside-0.4%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)GBX (26.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£143.51 million Net Margins-17.85% Pretax MarginN/A Return on Equity-48.56% Return on Assets-12.67% Debt Debt-to-Equity Ratio116.74 Current Ratio2.20 Quick Ratio1.67 Sales & Book Value Annual Sales£168.74 million Price / Sales4.35 Cash FlowGBX 201.90 per share Price / Cash Flow3.01 Book ValueGBX 67.70 per share Price / Book8.97Miscellaneous Outstanding Shares121,009,000Free FloatN/AMarket Cap£734.52 million OptionableNot Optionable Beta1.10 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (LON:OXB) was last updated on 6/18/2026 by MarketBeat.com Staff. From Our PartnersChina can’t stop buying gold. Here’s why that mattersChina has made 18 consecutive months of central bank gold purchases - and analysts believe the official number...Traders Agency | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredA 3M Oz. Historical Gold Resource And A Market That Hasn't Caught UpOne Canadian junior explorer controls a gold and copper system in British Columbia's Kootenay Golden Arc - a d...Wall Street Logic | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | Sponsored13,858%. Same setup. July 9th.Qualcomm returned 13,858%. Xilinx returned 6,900%. Linear Technology returned 11,694%. Each owned the physical...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oxford Biomedica plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Oxford Biomedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OXB Stock Alerts